Your browser doesn't support javascript.
Protease Inhibition-An Established Strategy to Combat Infectious Diseases.
Sojka, Daniel; Snebergerová, Pavla; Robbertse, Luïse.
  • Sojka D; Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Branisovská 1160/31, CZ-37005 Ceské Budejovice, Czech Republic.
  • Snebergerová P; Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Branisovská 1160/31, CZ-37005 Ceské Budejovice, Czech Republic.
  • Robbertse L; Faculty of Science, University of South Bohemia in Ceské Budejovice, Branisovská 1760c, CZ-37005 Ceské Budejovice, Czech Republic.
Int J Mol Sci ; 22(11)2021 May 28.
Article in English | MEDLINE | ID: covidwho-1256561
ABSTRACT
Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays-malaria and COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasmodium falciparum / Protease Inhibitors / Proteasome Endopeptidase Complex / Drug Development / SARS-CoV-2 / COVID-19 Drug Treatment / Malaria Type of study: Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Ijms22115762

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasmodium falciparum / Protease Inhibitors / Proteasome Endopeptidase Complex / Drug Development / SARS-CoV-2 / COVID-19 Drug Treatment / Malaria Type of study: Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Ijms22115762